Skip to Content

Hemagen Diagnostics Inc HMGN

Morningstar Rating
$0.00 0.00 (99.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

HMGN is trading at a 566% premium.
Price
$0.00
Fair Value
$8.88
Uncertainty
Extreme
1-Star Price
$3.89
5-Star Price
$4.47
Economic Moat
Fszpm
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HMGN is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.00
Bid/Ask
$0.00 / $0.02
Market Cap
$15.50
Volume/Avg
10,900 / 10,800

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
15

Valuation

Metric
HMGN
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
HMGN
Quick Ratio
0.34
Current Ratio
1.07
Interest Coverage
−0.93
Quick Ratio
No chart available

Profitability

Metric
HMGN
Return on Assets (Normalized)
−32.98%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
−22.91%
Return on Assets
No chart available
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
ZsdxbtrvzVrvg$565.6 Bil
Vertex Pharmaceuticals Inc
VRTX
WlmdvqpsTddkkv$127.8 Bil
Regeneron Pharmaceuticals Inc
REGN
PkgcpqxtlRjxgxs$118.7 Bil
Moderna Inc
MRNA
QqzwnthpmVmt$46.8 Bil
Alnylam Pharmaceuticals Inc
ALNY
PptjcdvZyhlb$29.7 Bil
argenx SE ADR
ARGX
TmhcpmvddNxlr$29.3 Bil
BioNTech SE ADR
BNTX
SpmtlpnGntx$20.7 Bil
Biomarin Pharmaceutical Inc
BMRN
PbmkwxmPrstr$16.1 Bil
United Therapeutics Corp
UTHR
KkhpmhkkXpy$15.0 Bil
Incyte Corp
INCY
HwstncxbPllzwp$13.5 Bil

Sponsor Center